EA201190064A1 - Соединения этанамина и их применение для лечения депрессии - Google Patents

Соединения этанамина и их применение для лечения депрессии

Info

Publication number
EA201190064A1
EA201190064A1 EA201190064A EA201190064A EA201190064A1 EA 201190064 A1 EA201190064 A1 EA 201190064A1 EA 201190064 A EA201190064 A EA 201190064A EA 201190064 A EA201190064 A EA 201190064A EA 201190064 A1 EA201190064 A1 EA 201190064A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
treatment
application
ethanamine
compounds
Prior art date
Application number
EA201190064A
Other languages
English (en)
Russian (ru)
Inventor
Майкл Балестра
Питер Бернштайн
Глен Эрнст
Уильям Фритце
Джон П. Маккаули
Дэвид Наджиель
Лихонг Шень
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42288011&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201190064(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of EA201190064A1 publication Critical patent/EA201190064A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13Dicarboxylic acids
    • C07C57/15Fumaric acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Confectionery (AREA)
EA201190064A 2008-12-24 2009-12-22 Соединения этанамина и их применение для лечения депрессии EA201190064A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14067308P 2008-12-24 2008-12-24
PCT/SE2009/051493 WO2010074647A1 (en) 2008-12-24 2009-12-22 Ethanamine compounds and their use for treating depression

Publications (1)

Publication Number Publication Date
EA201190064A1 true EA201190064A1 (ru) 2012-02-28

Family

ID=42288011

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201190064A EA201190064A1 (ru) 2008-12-24 2009-12-22 Соединения этанамина и их применение для лечения депрессии

Country Status (31)

Country Link
US (4) US8013165B2 (enExample)
EP (2) EP2610246A1 (enExample)
JP (1) JP5491524B2 (enExample)
KR (1) KR20110097996A (enExample)
CN (1) CN102333762B (enExample)
AR (1) AR074981A1 (enExample)
AU (1) AU2009330745B2 (enExample)
BR (1) BRPI0923476A2 (enExample)
CA (1) CA2748235A1 (enExample)
CL (1) CL2011001590A1 (enExample)
CO (1) CO6450688A2 (enExample)
CR (1) CR20110365A (enExample)
CU (1) CU24017B1 (enExample)
DO (1) DOP2011000205A (enExample)
EA (1) EA201190064A1 (enExample)
EC (1) ECSP11011161A (enExample)
GT (1) GT201100186A (enExample)
HN (1) HN2011001773A (enExample)
IL (1) IL213518A0 (enExample)
MX (1) MX2011006680A (enExample)
NI (1) NI201100131A (enExample)
NZ (1) NZ593282A (enExample)
PE (1) PE20120249A1 (enExample)
SA (1) SA109310013B1 (enExample)
SG (2) SG192510A1 (enExample)
SV (1) SV2011003962A (enExample)
TW (1) TWI442922B (enExample)
UA (1) UA106056C2 (enExample)
UY (1) UY32360A (enExample)
WO (1) WO2010074647A1 (enExample)
ZA (1) ZA201105441B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0923476A2 (pt) * 2008-12-24 2016-01-19 Astrazeneca Ab composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica
CN112250676B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氧杂环化合物
CN112279843B (zh) * 2020-11-24 2023-05-16 深圳市第二人民医院(深圳市转化医学研究院) 一种具有抗抑郁活性的含氮杂环化合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3422191A (en) 1965-01-21 1969-01-14 Synergistics Inc Compositions and methods for tranquilization employing salts of n-morpholine ethanol
GB1427026A (en) 1972-11-20 1976-03-03 Ici Ltd Synthetic film materials
JPS5756474B2 (enExample) 1973-05-26 1982-11-30
GB9320273D0 (en) 1993-04-01 1993-11-17 Fisons Corp Compound useful in therapy
US5455259A (en) 1987-02-06 1995-10-03 Fisons Corporation Compounds for the treatment of neurodegenerative disorders
SG52662A1 (en) 1988-08-12 1998-09-28 Astra Ab Arylkalkyl-amines and -amides having anticonvulsant and neuroprotective properties
JP2514855B2 (ja) 1990-08-08 1996-07-10 キッセイ薬品工業株式会社 光学活性なアラニンアニリド誘導体の酸付加塩
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
PT612314E (pt) * 1991-10-30 2000-06-30 Astra Ab Derivados de etilamina 2-heterociclicos e seu uso como produtos farmaceuticos
AU3897693A (en) 1992-04-03 1993-11-08 Astra Aktiebolag Enantiomeric 1-phenyl-2-(2-pyridinyl)ethylamine for the treatment of neurodegenerative disorders
EP0898566B1 (en) * 1996-04-19 2002-11-06 Akzo Nobel N.V. Substituted benzylamines and their use for the treatment of depression
EP0869122B1 (en) 1997-03-31 2002-12-04 Korea Research Institute Of Chemical Technology Quinolinic sulfide derivatives acting as NMDA receptor antagonists and process for preparation thereof
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
SE9901340D0 (sv) 1999-04-15 1999-04-15 Astra Pharma Prod Novel process
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
BRPI0923476A2 (pt) * 2008-12-24 2016-01-19 Astrazeneca Ab composto, métodos para tratar depressão em um ser humano, e grande distúrbio depressivo, e, composição farmacêutica

Also Published As

Publication number Publication date
EP2391606A4 (en) 2012-06-13
ECSP11011161A (es) 2011-07-29
CU20110141A7 (es) 2012-01-31
SG192510A1 (en) 2013-08-30
UA106056C2 (uk) 2014-07-25
SV2011003962A (es) 2012-01-06
US9035065B2 (en) 2015-05-19
HN2011001773A (es) 2014-08-18
AR074981A1 (es) 2011-03-02
TWI442922B (zh) 2014-07-01
AU2009330745A1 (en) 2011-08-04
ZA201105441B (en) 2012-03-28
US20120277272A1 (en) 2012-11-01
DOP2011000205A (es) 2011-07-15
IL213518A0 (en) 2011-07-31
TW201028149A (en) 2010-08-01
JP2012513993A (ja) 2012-06-21
JP5491524B2 (ja) 2014-05-14
NI201100131A (es) 2012-03-19
UY32360A (es) 2010-07-30
SA109310013B1 (ar) 2013-07-28
US20130137731A1 (en) 2013-05-30
US20100179199A1 (en) 2010-07-15
US20120115913A1 (en) 2012-05-10
BRPI0923476A2 (pt) 2016-01-19
CO6450688A2 (es) 2012-05-31
CN102333762B (zh) 2014-06-11
EP2391606A1 (en) 2011-12-07
AU2009330745B2 (en) 2012-04-05
US8013165B2 (en) 2011-09-06
CR20110365A (es) 2011-08-09
WO2010074647A1 (en) 2010-07-01
SG171928A1 (en) 2011-07-28
CA2748235A1 (en) 2010-07-01
GT201100186A (es) 2013-10-08
CU24017B1 (es) 2014-07-30
KR20110097996A (ko) 2011-08-31
EP2610246A1 (en) 2013-07-03
MX2011006680A (es) 2011-07-12
CN102333762A (zh) 2012-01-25
CL2011001590A1 (es) 2012-06-22
PE20120249A1 (es) 2012-04-19
NZ593282A (en) 2013-06-28

Similar Documents

Publication Publication Date Title
EA201190144A1 (ru) Изотиазолилоксифениламидины и их применение в качестве фунгицидов
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
EA200970402A1 (ru) Триазолопиридазиновые модуляторы протеинкиназ
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
UA106875C2 (uk) Тіадіазолілоксифеніламідини та їх застосування як фунгіцидів
EA201071264A1 (ru) Аминодигидротиазиновые производные в качестве ингибиторов bace для лечения болезни альцгеймера
UA115231C2 (uk) Сполуки імідазопіролідинонів
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
EA201390274A1 (ru) Борсодержащие малые молекулы
EA201171367A1 (ru) Винилиндазолильные соединения
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201270560A1 (ru) Спиропиперидиновые соединения и их фармацевтическое применение для лечения диабета
EA201001257A1 (ru) Модуляторы ampk (амф-активируемой протеинкиназы)
EA201490474A1 (ru) Аминохиназолины в качестве ингибиторов киназ
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
EA201100978A1 (ru) Схема приема агониста рецептора s1p
EA201200999A1 (ru) Способы лечения рака молочной железы
EA201400338A1 (ru) Производные аминопиримидина для применения в качестве модуляторов киназной активности
UA110983C2 (uk) Похідна 1,2,3,4-тетрагідрохіноліну, придатна для лікування діабету
EA201290642A1 (ru) Соединения и способы
EA201190293A1 (ru) Пролекарства триптолида
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения